Albumin-Bilirubin and Severity as Key Factors of Recovery in Patients With PA-HSOS Undergoing Transjugular Intrahepatic Portosystemic Shunt

Jian-Ji Dai, Xiaoxian Yang, Xiaogang Hu, Yi Deng, Jun Lü, Jiamin Wang, Gang Li, Jianghao HongAnnali 2025 · DOI

Abstract

Transjugular Intrahepatic Portosystemic Shunt (TIPS) is a safe and effective treatment for Pyrrolizidine Alkaloid-induced Hepatic Sinusoidal Obstruction Syndrome (PA-HSOS). This study identifies disease severity and the Albumin-Bilirubin (ALBI) grade as critical predictors for the timeline of radiological recovery in these patients.

Introduction

Hepatic sinusoidal obstruction syndrome (HSOS) is a serious condition where small hepatic veins become blocked, leading to internal congestion, portal hypertension, and potential organ failure. While often associated with chemotherapy in Western countries, PA-HSOS is prevalent in China due to the ingestion of pyrrolizidine alkaloid-containing herbs like Gynura segetum. When standard anticoagulation fails, TIPS serves as a vital rescue therapy. This study aims to quantify the recovery of liver architecture post-TIPS and identify the biomarkers that influence this timeline.

Methods

A retrospective analysis was conducted on 30 patients with PA-HSOS who underwent TIPS at Jinhua Municipal Central Hospital after failing medical therapy. The procedure involves creating a shunt to bypass hepatic congestion and reduce portal pressure.

Angiographic view of the TIPS procedure showing the stent placement within the liver to alleviate portal hypertension.

Researchers utilized the ALBI grade—an objective measure of liver function based solely on albumin and bilirubin levels—and CT imaging to monitor "radiological recovery," defined by the resolution of patchy enhancement and liver swelling. Multiple linear regression was employed to determine independent predictors of recovery time.

Key Results

The study reported a 100% survival rate during the follow-up period, with the portal pressure gradient (PPG) decreasing significantly from an average of 22.65 mmHg to 9.40 mmHg. While clinical symptoms like ascites resolved in a median of 52 days, full radiological recovery on CT scans took significantly longer, with a median of 196.5 days.

Trends in laboratory parameters (Hb, WBC, PLT, STB, Alb, ALT/AST, Scr, PT) from pre-procedure to one year post-TIPS, showing biochemical stabilization.

Key predictive factors for the speed of radiological recovery included:

  • ALBI Grade: Patients with ALBI Grade 2 recovered faster than those with Grade 3 (170 vs. 224 days).
  • Disease Severity: Mild/moderate cases recovered in approximately 162 days, compared to 218 days for severe/very severe cases.

Discussion

The findings suggest that the ALBI grade is a superior predictor of recovery compared to traditional scores like Child-Pugh in this population, likely because it captures the liver's physiological reserve more objectively. The significant "lag" between clinical symptom relief and physical architectural restoration highlights the need for continued radiological monitoring even after symptoms subside. Notably, the high safety profile of TIPS in this cohort—with no instances of overt hepatic encephalopathy—supports its use as a primary rescue intervention for PA-HSOS.

Limitations and Future Work

The study is limited by its small sample size (n=30), retrospective nature, and the lack of a non-TIPS control group. Future multi-center prospective trials are necessary to validate these findings and establish ALBI as a standard prognostic tool for managing PA-HSOS recovery.

Summary updated

Abstract

TIPS is a safe and effective treatment for PA-HSOS. Disease severity and ALBI grade are key factors in estimating the recovery time of liver CT radiological manifestations in patients with PA-HSOS.
BibTeX
@inproceedings{dai2025albumin,
  author = {Jian-Ji Dai and Xiaoxian Yang and Xiaogang Hu and Yi Deng and Jun Lü and Jiamin Wang and Gang Li and Jianghao Hong},
  title = {{Albumin-Bilirubin and Severity as Key Factors of Recovery in Patients With PA-HSOS Undergoing Transjugular Intrahepatic Portosystemic Shunt}},
  booktitle = {Annali},
  year = {2025},
  doi = {10.62713/aic.4033},
}
Figure